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The term “neurodevelopmental disorder” broadly encompasses conditions thought to arise early in development and includes 
schizophrenia, bipolar disorder and autism among others. These conditions share a number of genetic and environmental risk fac-
tors postulated to lead to common difficulties in socio-emotional processing, communication and cognitive function. The alterna-
tive position is that, while the same traits are affected across these conditions, the nature or direction in which they are modified 
may be distinct. MRI studies provide a rapidly expanding and rich database which we propose can be used to contribute to this 
debate. Anatomical likelihood estimation (ALE) is a method of meta-analysis applied to voxel-based MRI studies. We have 
adapted this method to explore the extent to which schizophrenia and bipolar disorder and schizophrenia and autism share a 
common brain structural phenotype. We will review this work here and discuss whether there is sufficient other evidence to justi-
fy a common framework for further research into the inter-relatedness of such conditions. 
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The endophenotype approach to schizophrenia and related 
disorders considers traits associated with the condition also 
observable in individuals who do not meet diagnostic crite-
ria. The strategy relies upon assuming a dimensional per-
spective. It allows the size of samples studied to be greatly 
expanded as unaffected individuals or relatives who show 
similar traits to individuals with the illness can be included. 
In this way the impact of confounds such as medication and 
illness chronicity are reduced. In this paper we exploit the 
endophenotype approach in a rather different manner. 
Symptoms in psychiatry are never pathognomonic. Individ-
uals with similar clusters of symptoms, response to treat-
ment and outcome are categorized into discrete diagnostic 
groupings, but often the distinctions between diagnostic 
groups are blurred. This challenge in defining the target 
condition can be considered to be a disadvantage. However, 
an alternative is to examine similarities across different 
conditions from an intermediate or endophenotype perspec-
tive and determine whether common causal mechanisms 
may be at work across diagnostic categories.  
1  Voxel-based MRI studies 
Schizophrenia, autism and bipolar disorder are increasingly 
recognized have some common genetic [1,2] and environ-
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mental risk factors [3]. These appear to result in a degree of 
phenotypic overlap, affecting social and emotional process-
es, executive function and communication [4–6]. Intermedi-
ate between shared risk factors and complex phenotypic 
expression is brain, thus common developmental pressures 
driving these conditions would be expected to impact upon 
a common brain substrate. Brain volume differences be-
tween individuals with neurodevelopmental conditions and 
unaffected participants can be mapped to a brain co-ordinate 
system using voxel-based morphometry (VBM) methods 
[7–9]. Compared to manual based tracing techniques, VBM 
has the advantage of being a largely automated means to 
explore whole brain. This helps to avoid measurement bias 
and permits assessment of every volume-element or “voxel” 
in brain. In contrast, “region-of interest” (ROI) techniques 
require a priori targets for brain measurement. Moreover, 
ROI targets largely comprise rather coarse, lobar level 
structures that can be reliably traced manually. The fi-
ne-grained analysis of brain offered by VBM has its own 
draw backs; it involves multiple image pre-processing rou-
tines and challenging statistical approaches which have var-
ied over many years in development. Never-the-less, a 
sizeable number of VBM studies of disorders such as au-
tism, bipolar disorder and schizophrenia has accumulated, 
allowing regional brain volume differences across disorders 
to be registered within a common co-ordinate system or 
atlas. This repository provides a rich resource to investigate 
the extent to which neurodevelopmental disorders share an 
intermediate neuroanatomical phenotype.  
2  Anatomical Likelihood Estimation (ALE) 
A synthesis of VBM data can be achieved through meta- 
analysis. There are a number of different options available 
to extract co-ordinates listed in individual case-control 
group studies and compute the locations most consistently 
reported to be affected by a given condition. One such 
method, anatomical likelihood estimation (ALE), treats the 
co-ordinates of brain regions with significant group differ-
ences reported across multiple studies, as the centre of a 3D 
Gaussian probability distribution [10,11]. Where multiple 
studies report co-ordinates in similar location, the probabil-
ity that a given locus is involved in the target disorder is 
therefore increased. The result is a probability map summa-
rizing brain regions that have most consistently been impli-
cated in the disorder across the majority of studies. These 
extend more traditional meta-analyses of manual based ROI 
approaches that, as mentioned above, are constrained to 
individual ROIs [12].  
3  ALE in schizophrenia 
We, and others, have used ALE and modifications based on 
ALE to examine brain volume in schizophrenia [13–16]. In 
general ALE based meta-analysis of the literature in schiz-
ophrenia confirms that the disorder is characterized by low-
er grey matter volumes in frontal, striato-limbic, and tem-
poral lobe regions evident from first presentation prior to 
drug treatment [17]. In an expanded application of ALE we 
examined illness “vulnerability” and “progression” in 
schizophrenia, finding that those with a vulnerability to 
schizophrenia, through shared genetic risk or because they 
suffer prodromal symptoms, also have lower grey matter 
volumes in frontotemporal regions [13]. The latter study 
indicated that gray matter abnormalities are more extensive 
in patients at first-episode and even more so in those who 
suffer chronic illness. This study was limited by the cross- 
sectional nature of the original studies contained therein. 
Clearly longitudinal studies are the optimal means to ad-
dress progression of illness and medication effects directly, 
but follow-up studies in schizophrenia are extremely chal-
lenging (though see [18,19]). The ALE approach therefore 
serves as a practical substitute, allowing a synthesis of 
cross-sectional data at different stages of illness and results 
agree that schizophrenia involves progressive abnormalities 
within a limbic cortico-striato-thalamic loop system. 
4  Dual disorder ALE 
4.1  Schizophrenia and bipolar disorder 
There have been fewer VBM studies of bipolar disorder. 
Never-the-less ALE has proven a useful tool to summarize 
the literature and examine whether schizophrenia and bipo-
lar disorder act upon the same regions of brain. In order to 
compare schizophrenia and bipolar disorder effects on brain 
volume, it is critical to account for multiple confounds of 
predisposition to illness, chronicity of illness and medica-
tion effects. In a preliminary assessment of overlap in brain 
regions affected by both conditions, Ellison-Wright and 
Bullmore [20] synthesized data available from a vast num-
ber of schizophrenia studies together with data from studies 
of bipolar disorder. This initial investigation gave a strong 
indication that these disorders do affect the same brain re-
gions, namely anterior cingulate and insula [20]. A potential 
limitation to this study was that the heterogeneous collec-
tion of schizophrenia studies returned a map of schizophre-
nia that covered widespread brain regions. Thus the “over-
lap” could have been, at least partly, a false positive, given 
the few data points from bipolar studies might have coin-
cided by chance with some part of the extensive schizo-
phrenia map. To address this issue we designed a “dual dis-
order” ALE study in which VBM studies of bipolar disorder 
were matched 1:1 to schizophrenia studies on variables such 
as duration of illness and medication exposure [21]. In addi-
tion we modified the ALE kernal to generate a joint map of 
brain regions affected by schizophrenia and bipolar disorder. 
This permitted extraction of the percentage contribution 
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made by studies of schizophrenia or bipolar disorder to the 
overall result. The pipeline for this modified ALE is shown 
in Figure 1, taken from our original publication [21]. 
In our dual disorder ALE analysis we found that schizo-
phrenia and bipolar studies made an almost equal contribu-
tion to the final result, with both conditions leading to lower 
grey matter in prefrontal cortex, thalamus, left caudate, left 
medial temporal lobe, and right insula in patients relative to 
controls [8]. In general any brain region implicated in bipo-
lar disorder was also implicated in schizophrenia. However, 
the brain was more extensively affected by schizophrenia— 
patients with schizophrenia had a bilateral pattern of lower 
grey matter volumes while bipolar disorder predominantly 
affected the right hemispheric. Patients with schizophrenia, 
but not bipolar disorder, had consistently lower grey matter 
volumes in the left amygdala and insula.  
These results support the stance that bipolar disorder and 
schizophrenia are on the same spectrum with substantial 
shared neuroanatomical phenotype. They fit with evidence 
for shared cognitive difficulties in each disorder which carry 
similar prognostic value [22]. The less extensive brain in-
volvement in bipolar disorder is also consistent with classi-
cal evidence for its more benign course leading some to 
speculate that mood symptoms in the psychosis-spectrum 
are a protective response which may herald a better progno-
sis [23]. However, perhaps the strongest evidence support-
ing a shared aetiology of these disorders comes from genet-
ics. Schizophrenia and bipolar disorder have common sus-
ceptibility genes such as COMT and neuregulin 1 [24,25]. 
COMT is contained on chromosome 22q11 along with mul-
tiple other genes implicated in behavioural disorders in-
cluding schizophrenia [26] and bipolar disorder [27]. More 
generally, in a study of more than 2 million families in 
Sweden, relatives of probands with one or other diagnosis 
were at substantial increased risk for either disorder [28]. 




Figure 1  Flow chart of dual disorder ALE quantification. 
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of schizophrenia and bipolar disorder is partly shared. Tak-
en together with evidence of a common neuroanatomical 
phenotype in schizophrenia and bipolar disorder, we agree 
with van Os and Kapur’s proposal that what is inherited in 
psychosis, and related brain maturation disorders, is not a 
specific condition but altered brain development [29].  
4.2  Schizophrenia and autism spectrum disorders 
The genetic and environmental influences modulating brain 
development in schizophrenia and bipolar disorder appear 
to be at work in other disorders affecting brain maturation. 
There is long-standing evidence for increased incidence of 
mood disorders and schizophrenia in the families of indi-
viduals with autism spectrum, especially those with Asper-
ger’s syndrome [30–35]. Examples of genes implicated in 
both schizophrenia and autism spectrum include those en-
coding synaptic proteins such as contactin-associated pro-
tein-2 (CNTNAP2) and Neurexin-1 (NRXN1) [1,2].  
However, the link between schizophrenia and autism is 
not straightforward. Crespi and Badcock [36] have proposed 
that schizophrenia and autism are “diametric opposites”. 
They contend that autism and schizophrenia are associated 
with reciprocal changes in gene regulatory pathways; in 
autism there is a functional gain which leads to brain over- 
growth and impoverished theory of mind; in schizophrenia 
there is down regulation causing brain under-growth and 
over attribution of intent [36]. Supporting his hypothesis, 
Crespi and colleagues [37] have summarized evidence from 
studies of copy number variants (CNVs) in each disorder 
and observe them to be associated with reciprocal variants 
at four loci where deletions predispose to one condition and 
duplications predispose to the other. Even so, the authors 
acknowledge that a number of specific gene markers for 
schizophrenia and autism are just the same and they cannot 
fully exclude out a partial genetic overlap in these condi-
tions [37].  
Common environmental risk factors are also associated 
with autism and schizophrenia, particularly prenatal expo-
sures such as maternal inflammation and vitamin D defi-
ciency [38–48]. We therefore hypothesized that this array of 
shared aetiological pressures acting in autism and schizo-
phrenia might lead to common neuroanatomical features. To 
test this we used our dual-disorder ALE approach to synthe-
size VBM studies of autism and schizophrenia and quantify 
the extent to which studies implicated similar brain regions 
in these conditions. The results from an autism-schizophre- 
nia ALE revealed that, compared to typically developing 
control groups, both conditions resulted in lower grey mat-
ter volumes in posterior cingulate, right parahippocampal 
gyrus, putamen and insula and left thalamus, implicating 
limbic cortical-striato-thalamic circuitry in evolution of 
these conditions [49]. Lower grey matter volume in left pu-
tamen was only evident in autism, whereas lower grey mat-
ter in left amygdala and left insula were associated with 
schizophrenia only.  
Our autism-schizophrenia ALE combined studies of ei-
ther classical autism, high functioning autism or Asperger’s 
syndrome into a single autism spectrum group. However, it 
should be acknowledged that autism is not a single disorder 
but a spectrum with wide phenotypic expression [50]. In-
deed we have previously suggested that, on the spectrum of 
complex neurodevelopmental disorders, which includes 
autism, schizophrenia and Asperger’s syndrome, our results 
indicate changes to brain anatomy in Asperger’s syndrome 
may be closer to schizophrenia [21]. This is not a new idea 
— many years ago Wolff described children with a diagno-
sis of schizoid personality disorder as phenotypically akin to 
the eponymous syndrome described by Asperger [51]. Most 
interestingly these children went on to develop schizophre-
nia spectrum disorders in adulthood. More recent investiga-
tions have revealed increased dopamine activity in the cau-
date in Asperger’s syndrome [52], reminiscent of schizo-
phrenia [53] as well as high paranoia scores [54] and “nega-
tive” symptoms in autism spectrum which respond to the 
anti-psychotic risperidone [55]. In addition to overlapping 
anatomical and genetic anomalies in basal ganglia loop sys-
tems in autism-schizophrenia spectrum conditions, the 
physiological functioning of this circuitry has been shown 
to be altered. Specifically sensorimotor gating impairment 
has been reported across schizophrenia, schizotypal person-
ality disorder, relatives of patients with schizophrenia, high 
functioning autism and Asperger’s syndrome [9,56–59]. 
These disorders have been described as a “family of sen-
sorimotor gating disorders” [60] and our results point to a 
common neuroanatomical basis for this endophenotype. 
These numerous contact points in aetiology and phenotypic 
expression of the neurodevelopmental disorders are unlikely 
to be explained by simple co-morbidity. We propose that 
they reflect a diagnostic overlap and encourage a broader 
examination of endophenotypes across these disorder cate-
gories.  
5  Limitations 
A limitation to our discussion of neuroanatomical pheno-
types, is difficulty directly comparing the 2 dual-disorder 
ALE studies. This is because in each analysis reviewed, the 
VBM studies included were matched according to some-
what different criteria. For example the bipolar disor-
der/schizophrenia ALE matched studies on illness duration 
and medication history and included studies of patients in 
receipt of psychotropic medication. In contrast, the au-
tism/schizophrenia ALE matched mainly treatment naïve 
patient studies. The impact of medication on morphology of 
cortico-striatal circuits is a critical issue in these studies. 
Anti-psychotic drugs appear to act to increase basal ganglia 
size [18,61]. This may represent a “normalising” effect, 
since prior to treatment first episode patients with schizo-
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phrenia tend to have smaller basal ganglia sizes [7,18,61]. 
However anti-psychotic drugs may also act to lower region-
al grey matter volumes in cortex, but the exact pattern and 
mechanism behind this observation is far from clear [18]. 
Mood stabilizing medications used to treat bipolar disorder 
are also considered to have a neuroprotective effect. The 
mood stabilizer lithium has been reported to cause grey cor-
tical volume increase after only 4 weeks [62]. Other mood 
stabilizers such as sodium valproate and carbamazepine are 
thought to have neuroprotective effects through their inter-
action with cell plasticity regulators such as brain-derived 
neurotrophic factor (BDNF), bcl-2, and mitogen-activated 
protein kinases [63]. Thus, in evaluating endophenotypes of 
neurdevelopmental disorders, it is crucial to consider the 
impact of drug treatment on expression of the phenotype. 
6  Conclusion 
In summary we believe that deeper exploration of endo-
phenotypes across diagnostic boundaries holds promise. 
Potentially a better understanding of common causal mech-
anisms will improve efforts to prevent or alleviate the diffi-
culties faced by individuals with a wide range of neurode-
velopmental conditions. However, it is important not to lose 
sight of the unique features which are specific to diagnoses 
within the spectrum so that in time intervention strategies 
can be better targeted towards the individual.  
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